Results on epidemiologic study on Oropharyngeal Candidiasis (OPC) in oncology were presented at the 51st ASTRO (American Society for Therapeutic Radiology and Oncology) Meeting in Chicago (From November 1st to November 5th).
Pr David Azria (Anticancer Center Montpellier) has presented the data collected in 35 public and private oncology centers.
This study of 2027 cancer patients revealed a 10% prevalence (total number of cases of a disease in a given population at a specific time) of OPC. Patients receiving a combination of chemotherapy and radiotherapy are more likely to suffer from OPC (22%) than those receiving chemotherapy or radiotherapy alone. Highest prevalence was seen in patients with head and neck cancer (30%). Local treatments, such as miconazole MBTù, amphotericin B or nystatin mouthwashes are usually prescribed, as per treatment guidelines. Treatment compliance is strongly increased with drugs administered once daily (miconazole MBT) versus treatments with multiple daily dosing (amphotericin B or nystatin mouthwashes).
* miconazole MBT: Mucoadhesive Buccal Tablet, Loramyc® in Europe
Also known as thrush is an oral fungal infection most common in individuals with weakened immune systems – particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.
Radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists comprise ASTRO’s more than 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals and cancer treatment centers around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. These teams, which often include a nutritionist and a social worker, treat more than 1 million cancer patients each year.